Docoh
Loading...

FATE Fate Therapeutics

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The following proposals were submitted to the stockholders at the 2021 Annual Meeting of Stockholders of the Company held on June 2, 2021:

(i) The election of three Class II Directors, as nominated by the Board of Directors, to hold office until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified;

(ii) The ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021;

(iii) A non-binding advisory vote to approve the compensation of the Company’s named executive officers as set forth in the Company’s Proxy Statement filed with the Securities and Exchange Commission on April 21, 2021 (the “Proxy Statement”); and

(iv) To amend and restate the Company’s Amended and Restated Certificate of Incorporation to increase the authorized number of shares of common stock from 150,000,000 to 250,000,000.

The proposals are described in detail in the Proxy Statement.

The number of shares of common stock entitled to vote at the annual meeting was 93,892,256. The number of shares of common stock present or represented by valid proxy at the annual meeting was 82,917,534. All matters submitted to a vote of the Company’s stockholders at the annual meeting were approved and all director nominees were elected.

The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

(a) Election of Class II Directors.

Director NomineeVotes ForVotes Withheld
Robert Hershberg, M.D., Ph.D.75,572,4711,592,200
William H. Rastetter, Ph.D.73,277,6603,887,011
Michael Lee76,997,343167,328


There were 5,752,863 broker non-votes regarding the election of directors.

(b) Ratification of Auditors.

Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the voting included 82,787,306 votes for, 104,207 votes against, and 26,021 votes abstained.

There were zero broker non-votes regarding this proposal.

(c) Non-binding Advisory Vote on Compensation of Named Executive Officers.

Votes ForVotes AgainstAbstain
75,621,3211,509,26734,083


There were 5,752,863 broker non-votes regarding this proposal.

(d) Amendment to the Company’s Amended and Restated Certificate of Incorporation.

Votes ForVotes AgainstAbstain
80,381,9952,442,37693,163


There were zero broker non-votes regarding this proposal.